Speciality Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Education Dialogues
    • Business Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Speciality Medical Dialogues
    • Editorial
    • News
        • Anesthesiology
        • Cancer
        • Cardiac Sciences
        • Critical Care
        • Dentistry
        • Dermatology
        • Diabetes and Endo
        • Diagnostics
        • ENT
        • Featured Research
        • Gastroenterology
        • Geriatrics
        • Medicine
        • Nephrology
        • Neurosciences
        • Nursing
        • Obs and Gynae
        • Ophthalmology
        • Orthopaedics
        • Paediatrics
        • Parmedics
        • Pharmacy
        • Psychiatry
        • Pulmonology
        • Radiology
        • Surgery
        • Urology
    • Practice Guidelines
        • Anesthesiology Guidelines
        • Cancer Guidelines
        • Cardiac Sciences Guidelines
        • Critical Care Guidelines
        • Dentistry Guidelines
        • Dermatology Guidelines
        • Diabetes and Endo Guidelines
        • Diagnostics Guidelines
        • ENT Guidelines
        • Featured Practice Guidelines
        • Gastroenterology Guidelines
        • Geriatrics Guidelines
        • Medicine Guidelines
        • Nephrology Guidelines
        • Neurosciences Guidelines
        • Obs and Gynae Guidelines
        • Ophthalmology Guidelines
        • Orthopaedics Guidelines
        • Paediatrics Guidelines
        • Psychiatry Guidelines
        • Pulmonology Guidelines
        • Radiology Guidelines
        • Surgery Guidelines
        • Urology Guidelines
    LoginRegister
    Speciality Medical Dialogues
    LoginRegister
    • Home
    • Editorial
    • News
      • Anesthesiology
      • Cancer
      • Cardiac Sciences
      • Critical Care
      • Dentistry
      • Dermatology
      • Diabetes and Endo
      • Diagnostics
      • ENT
      • Featured Research
      • Gastroenterology
      • Geriatrics
      • Medicine
      • Nephrology
      • Neurosciences
      • Nursing
      • Obs and Gynae
      • Ophthalmology
      • Orthopaedics
      • Paediatrics
      • Parmedics
      • Pharmacy
      • Psychiatry
      • Pulmonology
      • Radiology
      • Surgery
      • Urology
    • Practice Guidelines
      • Anesthesiology Guidelines
      • Cancer Guidelines
      • Cardiac Sciences Guidelines
      • Critical Care Guidelines
      • Dentistry Guidelines
      • Dermatology Guidelines
      • Diabetes and Endo Guidelines
      • Diagnostics Guidelines
      • ENT Guidelines
      • Featured Practice Guidelines
      • Gastroenterology Guidelines
      • Geriatrics Guidelines
      • Medicine Guidelines
      • Nephrology Guidelines
      • Neurosciences Guidelines
      • Obs and Gynae Guidelines
      • Ophthalmology Guidelines
      • Orthopaedics Guidelines
      • Paediatrics Guidelines
      • Psychiatry Guidelines
      • Pulmonology Guidelines
      • Radiology Guidelines
      • Surgery Guidelines
      • Urology Guidelines
    • Home
    • Latest News
    • Viagra prevents...

    Viagra prevents rebound Pulmonary Hypertension in infants

    Written by Dr. Kamal Kant Kohli Kohli Published On 2018-03-07T19:25:54+05:30  |  Updated On 7 March 2018 7:25 PM IST
    Viagra prevents rebound Pulmonary Hypertension in infants

    A drug epidemic as a result of indiscriminate, inappropriate prescription of benzodiazepines needs urgent attention.Dr.Jennifer Papac, Dr.Anna Lembke and colleagues in an article published in New England Journal of Medicine have drawn the attention of medical community towards this silently ticking bomb of overuse of benzodiazepines.They have very vividly brought shocking facts to the notice of all stakeholders and suggested measures to address the challenge.


    Salient Points -

    • Benzodiazepines, a class of drugs often used to treat anxiety and insomnia have more than dozen types and are most commonly prescribed psychotropic medications in United States.

    • Benzodiazepines have proven utility when they are used intermittently and for less than 1 month at a time. But when they are used daily and for extended periods, the benefits of benzodiazepines diminish and the risks associated with their use increase.

    • From 1996 to 2013, the benzodiazepine prescription rose from 8.1 million to 13.5 million, an increase of 67% and deaths from benzodiazepine overdose increased from 1135 to 8791.

    • The Food and Drug Administration (FDA) has approved benzodiazepines for a diverse set of clinical indications, including anxiety, insomnia, seizures, and acute alcohol withdrawal. These drugs are also prescribed off-label for many other conditions, such as restless legs syndrome and depression.

    • Highly potent new forms of benzodiazepines are increasingly penetrating the illicit market.

    • Coprescription rates of Benzodiazepines and Opioids has nearly doubled between 2001 and 2013, going from 9% to 17%.

    • Clinicians seem to be unaware of how addictive benzodiazepines can be.

    • Increased benzodiazepine use among the elderly is specially a cause of concern because of adverse effects which include increased risk for falls, fractures, motor vehicle accidents, impaired cognition, and dementia.

    • Despite Safety concerns, benzodiazepine use among the elderly is on the rise as clinicians often are unaware of the dangers these drugs pose to seniors.

    • Despite a reported decline in benzodiazepine use recently, it still remains inappropriately high — particularly in those aged 85 and older — which warrants further attention from clinicians and policy-makers.

    • According to a Study there is a decline in prevalent use and Incident use of benzodiazepines in United States, Canada and Australia.

    • In all three countries, rates of incident and prevalent use were highest among women.

    • Another cause of concern according to authors is that clinicians may be prescribing "Z-drugs," agents such as zopiclone and zolpidem, instead of benzodiazepines, in a mistaken belief that those products are safer.

    • There is need for discussions about the problem of overprescribing and overuse of benzodiazepines and its tapering in the media, among clinicians, policymakers, and educators.

    • The dangerous trend of diverting patients from Opioids to benzodiazepines needs to be discouraged and the attention towards the problem has to be as focussed as has been given to opioid problem.

    • The infrastructure to address the opioid epidemic may be harnessed to respond to dangerous trends in benzodiazepine overuse, misuse, and addiction as well.

    • Health insurance companies could review coverage and payment policies that contribute to overprescribing of benzodiazepines.

    • Efforts should also be made to shut down illegal online pharmacies and other drug-trafficking networks where people obtain illicit benzodiazepines, particularly superpotent analogues.


    For further reference log on to: DOI: 10.1056/NEJMp1715050

    BenzodiazepineDr Anna LembkeDr Jennifer PapacFDAFood and Drug AdministrationinsomniaNew England Journal of Medicinepulmonary hypertension

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    Dr. Kamal Kant Kohli Kohli
    Dr. Kamal Kant Kohli Kohli
      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 12 Oct 2022 7:06 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok